AtriCure, Inc. (ATRC) is a publicly traded Healthcare sector company. As of May 21, 2026, ATRC trades at $29.00 with a market cap of $1.44B and a P/E ratio of -288.90. ATRC moved +0.69% today. Year to date, ATRC is -28.43%; over the trailing twelve months it is -14.83%. Its 52-week range spans $25.52 to $43.18. Analyst consensus is strong buy with an average price target of $50.29. Rallies surfaces ATRC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded ATRC stock?
Recent politician trading activity in ATRC includes disclosures from Gilbert Cisneros and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
ATRC Key Metrics
Key financial metrics for ATRC
Metric
Value
Price
$29.00
Market Cap
$1.44B
P/E Ratio
-288.90
EPS
$-0.10
Dividend Yield
0.00%
52-Week High
$43.18
52-Week Low
$25.52
Volume
0
Avg Volume
0
Revenue (TTM)
$552.16M
Net Income
$-4.59M
Gross Margin
75.61%
Congressional Trades in ATRC
Gilbert Cisneros purchase ATRC on May 6, 2025 (amount: $15.00K).
Josh Gottheimer sale ATRC on Jun 18, 2024 (amount: $15.00K) for Joint.
Recent politician trading activity in ATRC includes disclosures from Gilbert Cisneros and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in ATRC?
Yes. Rallies tracks politician and congressional stock disclosures for ATRC, including reported purchases, sales, dates, owners, and trade amounts when available.
Is ATRC research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ATRC. It does not provide personalized investment advice.
